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Abstract: Tacrolimus (FK506), which was isolated from the fermentation broth of Streptomyces tsukubaensis No. 9993, 
has an immunosuppressive effect. In T-lymphocytes, FK506 binds to the intracellular receptor, a 12-kDa FK506-binding 
protein (FKBP12). The FK506-FKBP12 complex binds to the phosphatase calcineurin (CN) and inhibits the activity of CN. 
By inhibition of the activity of CN, dephosphorylation of a nuclear factor of activated T-cells (NFAT) is inhibited, and 
translocation of the NFAT to the nucleus is suppressed. Thereby, the production of T-cell-derived mediators such as inter-
leukin 2 (IL-2) is inhibited, and the proliferation of cytotoxic T-cells is suppressed. In muscle cells, FKBP12 and FKBP12.6 
are associated with ryanodine-sensitive Ca
2+ release channels (ryanodine receptors: RyRs) on the skeletal and cardiac 
muscle sarcoplasmic reticulum (SR), respectively. FK506 modulates the RyR by dissociating FKBP12 or FKBP12.6 from 
the RyR complex. FKBP12 is also associated with inositol 1,4,5-trisphosphate (IP3)-sensitive Ca
2+ release channels (IP3 
receptors: IP3Rs) on the endoplasmic reticulum (ER) of non-muscle cells. The IP3R-FKBP12 complex binds to CN, which 
dephosphorylates the protein kinase C (PKC) phosphorylation site on the receptor. When FKBP12 is dissociated from the 
IP3R complex by FK506, CN is also dissociated from the IP3R. Thereby, the IP3R is phosphorylated by PKC, and the recep-
tor is modulated. Recently, it was found that FK506 itself induces Ca
2+ release through RyRs in some tissues.
Keywords: ryanodine receptor, IP3 receptor, FK506, FKBP
Introduction
The immunosuppressant tacrolimus (FK506) was isolated from the metabolite of a streptomycete in 1984 
as a drug to inhibit T-cell activation [1]. In T-lymphocytes, FK506 binds to the intracellular receptor, a 
12-kDa FK506-binding protein (FKBP12) [2, 3]. The FK506-FKBP12 complex binds to the Ca
2+-activated 
phosphatase calcineurin (CN) and inhibits the activity of CN [4, 5]. CN dephosphorylates a nuclear factor 
of activated T-cells (NFAT) in the  cytoplasm [6]. The dephosphorylated NFAT is translocated to the nucleus 
[7] and induces the production of T-cell-derived mediators such as interleukin 2 (IL-2) via transcription 
of the gene. FK506 prevents the translocation of an NFAT to the nucleus via the inhibition of CN activity 
[7]. Therefore, the production of IL-2, which induces the proliferation of cytotoxic T-cells, is inhibited.
It was shown in the 1990’s that FKBP12 is tightly associated with ryanodine-sensitive Ca
2+ channels 
(ryanodine receptors: RyRs) on the sarcoplasmic reticulum (SR) of skeletal muscle [8, 9]. FK506 has 
been shown to promote dissociation of FKBP12 from the RyR complex [10] and to increase Ca
2+ release 
through the channel [10, 11]. In the cardiac muscle SR, FKBP12.6 is associated with RyRs [12, 13]. 
FKBP12 has been shown to be associated also with inositol 1,4,5-trisphosphate (IP3)-sensitive Ca
2+ 
channels (IP3 receptors: IP3Rs) on the endoplasmic reticulum (ER) of cerebellum tissues [14, 15]. The 
IP3R-FKBP12 complex binds to CN [15, 16], which dephosphorylates the protein kinase C (PKC) 
phosphorylation site on the IP3R [15]. When FKBP12 is dissociated from the IP3R complex by FK506, 
CN is also dissociated from the IP3R [15]. Thereby, the IP3R is phosphorylated by PKC, and Ca
2+ release 
through the receptor is increased [14]. Recently, it was shown that FK506 itself induces Ca
2+ release 
from the RyR in pancreatic acinar cells, probably via an FKBP-independent mechanism [17, 18].
In this review, the effects of FK506 as an immunosuppressant are described brieﬂ  y, and the effects 
of FK506 on Ca
2+ release channels of the SR or ER membrane are described in detail.
Chemicals
Tacrolimus (Fig. 1), a 23-membered macrolide lactone, was isolated from the fermentation broth of 
Streptomyces tsukubaensis No. 9993 in 1984 [1] and is designated by the code number of FK506. 52
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The drug is a colorless prism, and the molecular 
formula is C44H69NO12·H2O (Mw: 804.02). The 
chemical structure was determined by Tanaka et al. 
[19]. The drug is soluble in ethanol, methanol and 
DMSO and is insoluble in water.
Effects of FK506 as an 
Immunosuppressant
Cyclosporin A (CsA), a fungal metabolite, was a 
powerful immunosuppressive agent in the 1980’s 
and has been used as a therapeutic agent to prevent 
graft rejection following organ transplantation. 
CsA inhibits the production of T-cell-derived 
soluble mediators such as IL-2, which is induced 
by antigen stimulation in T-lymphocytes. FK506 
inhibits the production of IL-2 at about a one 
hundred-times lower concentration than that of 
CsA [20]. CsA and FK506 bind to intracellular 
receptors named cyclophilins [21, 22] and FKBPs 
[2, 3], respectively. Both receptors, called immu-
nophilins, are abundant, ubiquitous proteins within 
cells and comprise a family of proteins [23]. All 
immunophilins have cis-trans peptidyl-prolyl 
isomerase (PPIase) activity. It has been shown that 
the PPIase activity is inhibited by the binding of 
CsA and FK506 to immunophilins [2, 3, 24, 25]. 
However, the PPIase activities of cyclophilins and 
FKBPs are known to be unrelated to the immuno-
suppressive activities of CsA and FK506, respec-
tively. The major proteins of cyclophilins and 
FKBPs are cyclophilin A (CypA) and FKBP12, 
respectively. Both the CsA-CypA and FK506-
FKBP12 complexes can bind to the Ca
2+-activated 
phosphatase CN and inhibit the enzyme activity of 
CN [4, 5]. CN is activated by the increment of 
intracellular Ca
2+ concentrations following T-cell 
receptor stimulation by antigens and dephosphor-
ylates a cytosolic component of NFAT (NFATc) in 
the cytoplasm [6]. The NFATc dephosphorylated 
by CN is translocated to the nucleus [7] and com-
bines with a nuclear component of NFAT (NFATn) 
[7, 26]. The NFATc-NFATn complex binds to the 
regulatory site on the IL-2 promoter to activate 
transcription of the IL-2 gene [27]. CsA and FK506 
inhibit the translocation of NFATc to the nucleus 
via inhibition of CN activity [7] and therefore 
prevent transcription of the IL-2 gene. As a result 
of the inhibition of IL-2 production, the prolifera-
tion of cytotoxic T-cells that contribute to the 
destruction of target tissues is suppressed.
Ca
2+ Release Channels
In a variety of cell types, intracellular Ca
2+ stores 
play an essential role in the regulation of cytosolic 
Ca
2+ concentration, the elevation of which triggers 
many cellular events, such as muscle contraction, 
enzyme secretion, cell proliferation and egg 
fertilization. Two distinct classes of Ca
2+ release 
channels, which induce the release of Ca
2+ from 
the stores into the cytosol, have been identiﬁ  ed.
One is sensitive to the ubiquitous second mes-
senger IP3 that is formed by stimulation of a cell 
surface receptor with hormones or neurotransmit-
ters [28]. Ca
2+ channels (receptors) sensitive to IP3 
(IP3Rs) are widely distributed on the ER of many 
tissues, including T-lymphocytes. The channel 
protein has been puriﬁ  ed [29] and cloned [30, 31] 
in brain tissues. Three IP3R isoforms (IP3R1, IP3R2 
and IP3R3) are expressed [32, 33]. IP3R1, the major 
type of IP3R, is widely expressed in the rodent 
brain, predominantly in cerebellar Purkinje cells. 
IP3R2 is expressed in glial cells. IP3R3 is expressed 
in the kidney, pancreatic islets and intestinal 
epithelium.
The other is sensitive to the plant alkaloid 
ryanodine. Ca
2+ channels (receptors) sensitive to 
ryanodine (RyRs) are activated by caffeine, 
ryanodine and Ca
2+. The channel protein has been 
puriﬁ  ed [34, 35] and cloned [36, 37] in the skeletal 
and cardiac muscle SR. RyRs were also character-
ized in the ER of non-muscle cells, including brain 
cells [38], liver cells [39] and exocrine cells [40]. 
It has been shown that three RyR isoforms (RyR1, 
RyR2 and RyR3) are expressed [41–43]. RyR1 and 
RyR2 have been found to be localized in skeletal 
muscle and cardiac muscle, respectively, while 
RyR3 is found in the brain and smooth muscle. 
Figure 1. Chemical structure of tacrolimus (FK506).53
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Recently, it was shown that the endogenous NAD
+ 
metabolite cyclic ADP-ribose (cADPR) induces 
Ca
2+ release from RyRs in sea urchin eggs [44, 45], 
cardiac muscle cells [46], brain cells [47] and pan-
creatic β cells [48]. This compound is thought to 
be an intracellular messenger in addition to IP3 [49]. 
It has also been shown that a low concentration of 
cADPR can modulate the RyR [17, 50, 51].
Effects of FK506 on Ca
2+ 
Release Channels
FK506 is known to modulate RyRs. In the skel-
etal muscle SR, RyR1 is tightly associated with 
FKBP12 [8, 9]. It has been found that one mole 
of FKBP12 is associated with each protomer of 
homotetrameric RyR1 [10]. In association with 
RyR1, FKBP12 has been shown to stabilize the 
closed conformation of the Ca
2+ release channel 
[10]. FK506 has been shown to promote disso-
ciation of FKBP12 from the RyR1 complex [10]. 
The EC50 value for dissociation of FKBP12 from 
the RyR1 complex in skeletal muscle has been 
reported to be in the concentration range of 0.12 
to 0.5 µM FK506 [10]. By the removal of 
FKBP12, RyR1 exhibits subconductance states 
[11], and the Ca
2+ or caffeine sensitivity of the 
channel is enhanced [10, 52]. Compared with 
control SR vesicles, FKBP12-deﬁ  cient SR vesi-
cles have been shown to increase open probabil-
ity and mean open times for single channel 
recordings of the receptor [52].
In cardiac type RyR (RyR2), FKBP12.6 binds 
to the receptor [12, 13, 53]. FK506 is known to 
activate or modulate RyR2 by the removal of 
FKBP12.6. FKBP12.6-deﬁ  cient cardiac SR Ca
2+ 
channels did not increase the open probability for 
single channel recordings as was the case of 
FKBP12-deﬁ  cient skeletal SR Ca
2+ channels [13]. 
Although the type of RyR is unclear, it has been 
shown that FK506 (0.1–100 µM) increases the 
open probability of reconstituted RyRs (Ca
2+ 
channels) in coronary arterial smooth muscle cells, 
in which FKBP12.6 was detected [54]. This result 
suggests that FK506 activates the RyR in this tissue 
by the removal of FKBP12.6. It has been shown 
that FK506 at a micromolar concentration range 
induces Ca
2+ release from RyR2 of pancreatic islet 
microsomes by dissociating FKBP12.6 [53]. 
Recently, it was shown that FK506 (3 µM) shifts 
the dose-response curve of ryanodine- or caffeine-
induced 
45Ca
2+ release from the microsomal 
vesicles of rat pancreatic acinar cells to the left 
[17]. Since an RyR2 isoform has been identiﬁ  ed 
in rat pancreatic acinar cells [55, 56], FKBP12.6 
may be involved in the modulation of Ca
2+ release 
through the RyR by FK506. It has been found that 
cADPR as well as FK506 can bind to FKBP12.6 
and dissociate FKBP12.6 from pancreatic islet 
microsomes to release Ca
2+ [53]. An antibody 
against FKBP12.6 has been shown to inhibit acti-
vation of the RyR induced not only by FK506 but 
also by cADPR in coronary arterial smooth muscle 
cells [54]. These ﬁ  ndings suggest that cADPR dis-
sociates FKBP12.6 from the RyR-FKBP12.6 
complex to activate the Ca
2+ channel. It has been 
found in rat pancreatic acinar cells that cADPR 
shifts the dose-response curve of ryanodine- or 
caffeine-induced 
45Ca
2+ release to the left by the 
same extent as that in the case of FK506 and that 
the stimulatory effects on ryanodine- or caffeine-
induced 
45Ca
2+ release by cADPR and by FK506 
are not additive [17]. The results suggest that 
cADPR modulates the RyR in pancreatic acinar 
cells by the same mechanism as that by which 
FK506 modulates the RyR. The endogenous ligand 
cADPR might induce activation or modulation of 
the RyR by the removal of FKBP12.6 from the 
RyR complex under physiological conditions. It 
has been shown that protein kinase A (PKA), which 
is activated by adrenergic stimulation of cardiac 
muscle cells, phosphorylates Ser 2809 on RyR2 of 
the canine heart [57]. The RyR2 phosphorylated 
by PKA dissociates FKBP12.6 from the receptor 
and increases open probability of the channel [57, 
58]. In heart failure, the adrenergic receptor is 
chronically stimulated. The phosphorylation of 
RyR2 by PKA in failing hearts of humans and 
canines is increased by ∼4 fold compared with that 
in nonfailing hearts [57]. The hyperphosphoryla-
tion of RyR2 by PKA in failing hearts results in a 
depletion of FKBP12.6 from the RyR2 complex 
[57, 59] and an abnormal Ca
2+ leak through the 
RyR2 [60, 61].
IP3R1, a structurally related tetramer that has 
up to 40% sequence identity with RyR1 [30, 31, 
33], associates with FKBP12 [14, 15]. It has been 
found that FKBP12 binds to the IP3R1 of the rat 
cerebellum at residues 1400–1401, a leucyl-prolyl 
dipeptide that is an FK506-like domain [16]. The 
EC50 value for dissociation of FKBP12 from the 
IP3R1 complex in the rat cerebellum has been 
shown to be in the concentration range of 10 to 
100 nM FK506 [15]. The IP3R1-FKBP12 complex 54
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can associate with CN [15, 16]. CN has been shown 
to dephosphorylate the PKC phosphorylation site 
on IP3R1 [15]. When FKBP12 is dissociated from 
the IP3R1 complex by FK506, binding of CN to 
the FK506-FKBP12 complex is stimulated [15]. 
Thereby, IP3R1 is phosphorylated by PKC, and 
Ca
2+ ﬂ  ux through IP3R1 is increased [14]. Under 
physiological conditions, increase in Ca
2+ release 
from the ER to the cytosol through the IP3R by 
PKC activation activates CN, and the activated 
CN decreases Ca
2+ release by dephosphorylation 
of the receptor. Thus, the increase and decrease 
in Ca
2+ release through IP3R mediate Ca
2+ oscil-
lations [15].
It is known that FK506 itself induces Ca
2+ 
release from the ER of non-muscle cells. It has 
been shown that FK506 induces Ca
2+ release 
through the RyR in pancreatic islets by the removal 
of FKBP12.6 as mentioned above [53]. Recently, 
it was shown that FK506 induces a biphasic 
45Ca
2+ 
release from the ER of pancreatic acinar cells [18]. 
The first phase of the FK506-induced 
45Ca
2+ 
release was seen at concentrations up to 10 µM 
(Km = 0.5 µM), and the second phase of the release 
was seen at concentrations over 10  µM 
(Km = 55 µM). The ﬁ  rst phase of the release was 
stimulated by the presence of cADPR [17]. The 
FK506-induced response caused by the dissocia-
tion of FKBP should be reduced in the presence 
of cADPR, since it is thought that FKBP had been 
removed from the RyR by cADPR before the 
addition of FK506. It is unlikely that the FK506 
(10 µM)-induced 
45Ca
2+ release in pancreatic 
acinar cells is due to the dissociation of FKBP. 
FK506 is a compound with a macrocyclic lactone 
ring structure (Fig. 1). It has been shown that 
rapamycin and ivermectin, macrocyclic lactone 
derivatives, increased the open probability of 
FKBP12-stripped RyRs in skeletal muscle [62, 
63]. This ﬁ  nding suggests that the compounds 
activate the RyR by a mechanism other than dis-
sociation of FKBP. The ﬁ  rst phase of the FK506-
induced 
45Ca
2+ release in pancreatic acinar cells 
may be explained by a direct activation of the RyR 
by FK506. The second phase of the FK506-
induced 
45Ca
2+ release in pancreatic acinar cells 
was inhibited by heparin, an inhibitor of the IP3R 
[18]. Although it is unclear whether FKBP is 
involved in the second phase of the FK506-
induced release, there is a possibility that FK506 
(10 µM) directly activates the IP3R in pancreatic 
acinar cells.
Conclusion
FKBPs are abundant and ubiquitous proteins 
within cells. FKBP12 or FKBP12.6 binds to the 
RyR on the SR or ER and regulates Ca
2+ release 
from the receptor to the cytosol. FK506 dissociates 
FKBP12 or FKBP12.6 from the RyR complex and 
increases Ca
2+ release through the receptor. In 
addition, the FK506-FKBP12 complex binds to 
the phosphatase CN and inhibits the enzyme activ-
ity of CN. In T-lymphocytes, dephosphorylation 
of an NFAT by CN is inhibited by FK506. There-
fore, translocation of the NFAT to the nucleus is 
inhibited, and the immunoreaction of T-cells is 
suppressed. FKBP12 and CN bind to the IP3R on 
the ER. When FKBP12 is dissociated from the IP3R 
complex by FK506, CN is also dissociated from 
the receptor. Thereby, the IP3R is phosphorylated 
by PKC, and the Ca
2+ release through the IP3R is 
increased. FK506 has been used as a tool to eluci-
date the pathway of immunoreaction and the 
modulation mechanism of Ca
2+ release from the 
SR or ER. With elucidation of the action of FK506 
and the cellular functions of FKBPs, FK506 may 
become more widely used in biomedical 
research.
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